Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia
A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2 b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leu...
Gespeichert in:
| Veröffentlicht in: | Blut 1987-11, Vol.55 (5), p.453-458 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 458 |
|---|---|
| container_issue | 5 |
| container_start_page | 453 |
| container_title | Blut |
| container_volume | 55 |
| creator | KLOKE, O BECHER, R NIEDERLE, N |
| description | A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2 b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leucocyte counts despite dose escalation (up to 7 x 10(6) IU/day s.c.). Subsequent treatment with recombinant Interferon gamma failed to control myeloid proliferation. However, combined administration of both Interferon alpha and Interferon gamma resulted in a renewed haematological remission which lasted six months. |
| doi_str_mv | 10.1007/BF00367463 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00367463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81104522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-5d66ff29d6b904ff4392961d7ed0bf15d6410ca6991d694bbc978b6beaa75d243</originalsourceid><addsrcrecordid>eNpNkUGLFDEQhYMo6-zqxbuQg3gQWpN0Ot05uou7CguC6LmpTioz0STdJt2H-Rv-YjPssHqqot5Xj6IeIa84e88Z6z9c3zLWql6q9gnZcdmKhnWDfEp2jDHVdEKK5-SylJ-Mda0Y-gty0XI-aC125M83LMucCtJ1pusBqZnj5BNaCjb65MuaYfVzorOjPq2YHeaKUwjLASgkS_cQY-1c1agDH7aMJ7j4tA_4387JPcNyrCNqDnXgDY1HDPMe07wVGnD7BRg9vCDPHISCL8_1ivy4_fT95nNz__Xuy83H-8YIodams0o5J7RVk2bSOdlqoRW3PVo2OV5lyZkBpTW3SstpMrofJjUhQN9ZIdsr8vbBd8nz7w3LOkZfDIYACetB48A5k50QFXz3AJo8l5LRjUv2EfJx5Gw8BTD-C6DCr8-u2xTRPqLnj1f9zVmHYiC4DMn48oj1Xa9VNfsLPiOQRA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81104522</pqid></control><display><type>article</type><title>Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>KLOKE, O ; BECHER, R ; NIEDERLE, N</creator><creatorcontrib>KLOKE, O ; BECHER, R ; NIEDERLE, N</creatorcontrib><description>A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2 b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leucocyte counts despite dose escalation (up to 7 x 10(6) IU/day s.c.). Subsequent treatment with recombinant Interferon gamma failed to control myeloid proliferation. However, combined administration of both Interferon alpha and Interferon gamma resulted in a renewed haematological remission which lasted six months.</description><identifier>ISSN: 0006-5242</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/BF00367463</identifier><identifier>PMID: 3118992</identifier><identifier>CODEN: BLUTA9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Antineoplastic agents ; Biological and medical sciences ; Bone Marrow - pathology ; Chemotherapy ; Drug Therapy, Combination ; Humans ; Interferon Type I - adverse effects ; Interferon Type I - therapeutic use ; Interferon-gamma - adverse effects ; Interferon-gamma - therapeutic use ; Leukemia, Myeloid - drug therapy ; Leukemia, Myeloid - pathology ; Male ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Blut, 1987-11, Vol.55 (5), p.453-458</ispartof><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c226t-5d66ff29d6b904ff4392961d7ed0bf15d6410ca6991d694bbc978b6beaa75d243</citedby><cites>FETCH-LOGICAL-c226t-5d66ff29d6b904ff4392961d7ed0bf15d6410ca6991d694bbc978b6beaa75d243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7579600$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3118992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KLOKE, O</creatorcontrib><creatorcontrib>BECHER, R</creatorcontrib><creatorcontrib>NIEDERLE, N</creatorcontrib><title>Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia</title><title>Blut</title><addtitle>Blut</addtitle><description>A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2 b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leucocyte counts despite dose escalation (up to 7 x 10(6) IU/day s.c.). Subsequent treatment with recombinant Interferon gamma failed to control myeloid proliferation. However, combined administration of both Interferon alpha and Interferon gamma resulted in a renewed haematological remission which lasted six months.</description><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow - pathology</subject><subject>Chemotherapy</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Interferon Type I - adverse effects</subject><subject>Interferon Type I - therapeutic use</subject><subject>Interferon-gamma - adverse effects</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Leukemia, Myeloid - drug therapy</subject><subject>Leukemia, Myeloid - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0006-5242</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkUGLFDEQhYMo6-zqxbuQg3gQWpN0Ot05uou7CguC6LmpTioz0STdJt2H-Rv-YjPssHqqot5Xj6IeIa84e88Z6z9c3zLWql6q9gnZcdmKhnWDfEp2jDHVdEKK5-SylJ-Mda0Y-gty0XI-aC125M83LMucCtJ1pusBqZnj5BNaCjb65MuaYfVzorOjPq2YHeaKUwjLASgkS_cQY-1c1agDH7aMJ7j4tA_4387JPcNyrCNqDnXgDY1HDPMe07wVGnD7BRg9vCDPHISCL8_1ivy4_fT95nNz__Xuy83H-8YIodams0o5J7RVk2bSOdlqoRW3PVo2OV5lyZkBpTW3SstpMrofJjUhQN9ZIdsr8vbBd8nz7w3LOkZfDIYACetB48A5k50QFXz3AJo8l5LRjUv2EfJx5Gw8BTD-C6DCr8-u2xTRPqLnj1f9zVmHYiC4DMn48oj1Xa9VNfsLPiOQRA</recordid><startdate>198711</startdate><enddate>198711</enddate><creator>KLOKE, O</creator><creator>BECHER, R</creator><creator>NIEDERLE, N</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198711</creationdate><title>Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia</title><author>KLOKE, O ; BECHER, R ; NIEDERLE, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-5d66ff29d6b904ff4392961d7ed0bf15d6410ca6991d694bbc978b6beaa75d243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow - pathology</topic><topic>Chemotherapy</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Interferon Type I - adverse effects</topic><topic>Interferon Type I - therapeutic use</topic><topic>Interferon-gamma - adverse effects</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Leukemia, Myeloid - drug therapy</topic><topic>Leukemia, Myeloid - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KLOKE, O</creatorcontrib><creatorcontrib>BECHER, R</creatorcontrib><creatorcontrib>NIEDERLE, N</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KLOKE, O</au><au>BECHER, R</au><au>NIEDERLE, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia</atitle><jtitle>Blut</jtitle><addtitle>Blut</addtitle><date>1987-11</date><risdate>1987</risdate><volume>55</volume><issue>5</issue><spage>453</spage><epage>458</epage><pages>453-458</pages><issn>0006-5242</issn><eissn>1432-0584</eissn><coden>BLUTA9</coden><abstract>A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2 b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leucocyte counts despite dose escalation (up to 7 x 10(6) IU/day s.c.). Subsequent treatment with recombinant Interferon gamma failed to control myeloid proliferation. However, combined administration of both Interferon alpha and Interferon gamma resulted in a renewed haematological remission which lasted six months.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><cop>New York, NY</cop><pub>Springer</pub><pmid>3118992</pmid><doi>10.1007/BF00367463</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-5242 |
| ispartof | Blut, 1987-11, Vol.55 (5), p.453-458 |
| issn | 0006-5242 1432-0584 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00367463 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Antineoplastic agents Biological and medical sciences Bone Marrow - pathology Chemotherapy Drug Therapy, Combination Humans Interferon Type I - adverse effects Interferon Type I - therapeutic use Interferon-gamma - adverse effects Interferon-gamma - therapeutic use Leukemia, Myeloid - drug therapy Leukemia, Myeloid - pathology Male Medical sciences Pharmacology. Drug treatments |
| title | Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A15%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20the%20combined%20administration%20of%20interferons%20alpha%20and%20gamma%20after%20failure%20of%20single%20interferon%20therapy%20in%20chronic%20myelogenous%20leukaemia&rft.jtitle=Blut&rft.au=KLOKE,%20O&rft.date=1987-11&rft.volume=55&rft.issue=5&rft.spage=453&rft.epage=458&rft.pages=453-458&rft.issn=0006-5242&rft.eissn=1432-0584&rft.coden=BLUTA9&rft_id=info:doi/10.1007/BF00367463&rft_dat=%3Cproquest_cross%3E81104522%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=81104522&rft_id=info:pmid/3118992&rfr_iscdi=true |